Skip to main content
ADBIOTECH Co.,Ltd. logo

ADBIOTECH Co.,Ltd. — Investor Relations & Filings

Ticker · 179530 ISIN · KR7179530001 KO Manufacturing
Open in API
Filings indexed 425 across all filing types
Latest filing 2026-06-05 Major Shareholding Noti…
Country KR South Korea
Listing KO 179530

About ADBIOTECH Co.,Ltd.

http://www.adbiotech.com

ADBIOTECH Co., Ltd. is a biotechnology company specializing in the development and commercialization of immune antibodies. The company's core competency is IgY (Immunoglobulin in Yolk) technology, which utilizes antibodies derived from eggs to create alternatives to conventional vaccines and antibiotics. Its product portfolio targets the livestock, aquaculture, and human health sectors, with applications for disease prevention and treatment in animals like salmon and shrimp, as well as human-focused developments for conditions related to Helicobacter pylori and cholesterol. The company manages the entire value chain from research and development to production and sales. ADBIOTECH is also expanding its technological capabilities into VHH (nanobody) technology, with a strategic focus on the global companion animal market.

Recent filings

Filing Released Lang Actions
주식등의대량보유상황보고서(일반)
Major Shareholding Notification Classification · 95% confidence The document is a detailed statutory report filed under Korea’s Capital Market Act Article 147 disclosing a large shareholding position and changes by an investor (BK Partners Investment Association No.1) in the stock of AddBioTech. It provides extensive tables on share counts, ownership percentages, special relationships, change reasons and fund sources. This matches a "Major Shareholding Notification" rather than an earnings release, director change, or other category.
2026-06-05 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 93% confidence The document is titled “임원ㆍ주요주주 특정증권등 소유상황보고서,” i.e. a regulatory filing by executives and major shareholders disclosing their holdings and transactions in company securities. It is submitted to the Financial Services Commission and Korean Exchange and provides detailed share counts, percentages, and acquisition/disposition events. This matches the ‘Director’s Dealing’ category for insider personal share transactions (insider ownership disclosures), not an earnings release or general report. Hence it is classified as DIRS.
2026-06-05 Korean
최대주주인명목회사·조합등의최대주주변경
Major Shareholding Notification Classification · 82% confidence The document is a shareholder disclosure detailing the change in the company’s ultimate major shareholder (the nominal company/partnership). It lists pre- and post-transaction share counts and ownership percentages, the date of share transfer, and related details of the new and former major shareholders. This is a notification of a significant shareholding change rather than a financial report, dividend notice, or board change. Therefore, it falls under “Major Shareholding Notification.”
2026-06-04 Korean
[기재정정]주요사항보고서(유상증자결정)
Share Issue/Capital Change Classification · 91% confidence The document is a Korean major matters report (“주요사항보고서”) detailing a paid-in capital increase by third-party allotment (“유상증자결정”), including share numbers, issuance price, allocation details, and multiple corrections. This is a direct announcement of a share issue/capital change rather than an earnings release or management commentary. It therefore falls under the Share Issue/Capital Change category.
2026-06-04 Korean
증권발행결과(자율공시)
Share Issue/Capital Change Classification · 90% confidence The document is a voluntary disclosure reporting the results of a paid-in capital increase via third‐party allotment (common share issuance), detailing the number of shares issued, the amount raised, board resolution date, payment date, and planned listing. This clearly falls under announcements of new share issues/capital changes.
2026-06-04 Korean
[기재정정]주요사항보고서(전환사채권발행결정)
Capital/Financing Update Classification · 85% confidence The document is a Korean ‘주요사항보고서(전환사채권 발행결정)’ (Material Event Report on the issuance of convertible bonds) including full terms of the bond issuance, conversion mechanics, maturity, put options, etc. This is clearly a corporate financing update concerning issuance of new debt (convertible bonds) and amendment (“정정신고”) to the prior filing. It is neither a full annual or interim report nor a management or governance statement, but a specific update on fundraising/financing activity. Therefore it falls under the Capital/Financing Update category (CAP).
2026-06-04 Korean

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.